Review Article CORONARY STENTS - PAST, PRESENT AND FUTURE.
|
|
- Juliana Harrington
- 8 years ago
- Views:
Transcription
1 Review Article CORONARY STENTS - PAST, PRESENT AND FUTURE. VV JAIN*, S YELWATKAR**, OP GUPTA*** Introduction The advent of period of angioplasty has revolutionized the practice of interventional cardiology. After their introduction in mid 1980s there has been paradigm shift in cardiology practice making percutaneous coronary intervention (PCI) one of the most frequently performed invasive medical procedure today 1. History of Coronary Stents In 1964 Charles Theodore Dotter and Melvin P Judkins described the first angioplasty. In 1978 Andreas Gruntzig performed the first ballon angioplasty (POBA), a revolutionary and landmark treatment in cardiology. In the past 34 years since Gruntzig's ballon angioplasty, the technique of PCI has undergone tremendous growth and has surpassed coronary artery by-pass surgery(cabg).the field has seen some remarkable milestones with introduction of intracoronary stents, adjunctive antiplatelet therapy, drug-eluting stents etc 2. There was no doubt that POBA was a revolutionary treatment but came with its own drawbacks of acute vessel closure and restenosis 3. This fueled the discovery of a coronary stent. Puel and Sigwart, in 1986, deployed the first coronary stent to act as a scaffold and by this bare metal, self-expanding stent (BMS), known as the "Wall" stent was able to provide *Assistant Professor, **Associate Professor, *** Senior Consultant and Professor, Deptt of Medicine, MGIMS. a scaffold that prevented acute vessel closure and late constrictive recoil 5. In addition to restenosis, PTCA and BMS implantation cause exaggerated endothelial injury and inflammation, rendering both the stent and vessel highly thrombogenic. So although these initial stents were a respite to the abrupt vessel closure but there was an 18% chance of sub acute thrombotic coronary artery occlusion within 2 weeks of implantation 6 which required aggressive anticoagulant therapy. Later there were two landmark trials, BENESTENT (Belgian Netherlands Stent) trial 7 and the STRESS (Stent Restenosis Study) 8, which emphatically advocated that stenting was safe without anticoagulation therapy, with the use of dual antiplatelet therapy (DAPT) 9 and/or adequate stent deployment 10. Following these trials there was a phenomenal increase in the number of PCI performed which was approximately 84% in the year But soon it was discovered that in addition to the problem of sub acute thrombosis there was an iatrogenic problem of in-stent neointimal hyperplasia leading to stent restenosis. To tackle these problems, drug-eluting stents (DES) were introduced in 2001 as a strategy to minimize restenosis and requirement for reintervention. The DES increased the confidence of cardiologists to such an extent that the lesions that were earlier considered to be tackled only 1
2 Coronary stents - past, present and future. by CABG were subjected successfully to PCI with DES. The scenario changed so completely that in 2005 out of all revascularization procedures, 80-90% was with DES 11. But all things have a downside and era of DES was marked with rising safety concerns over these devices. Current status of DES The early period before the discovery of Sirolimus eluting stents was marked by overcoming challenges of delivery of Sirolimus (earlier called Rapamycin-a macrolide antibiotic, with properties of inhibition of cytokine and growth factor mediated proliferation of lymphocytes and smooth muscle cells,) either systemically or locally to prevent neointimal proliferation. But this was followed by the first human DES implant performed by J Eduardo Sausa in Sao Paulo in After this Sirolimus DES was commercially launched (CYPER SES) and was highly recommended by numerous large studies. The Cypher SES was initially evaluated in the pivotal RAVEL (Randomized Study With the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with De Novo Native Coronary Artery Lesions) study, which randomly assigned 238 patients with relatively low risk lesions to treatment with the Cypher SES or BMS as controls. At 1-year follow-up, the rate of binary stenosis was 0.0% and 26.6% for patients treated with Cypher SES and BMS, respectively 13. Following this there were numerous clinical trials which advocated the use of DES (CYPER SES) over BMS due to significant reductions in angiographic in-stent late loss, in- stent angiographic restenosis and repeat revascularization at follow up. Table 1: Indications for use of drug eluting stents 14, "On-label" or FDA-approved use For improving coronary luminal diameter in patients with symptomatic ischemic disease due to discrete de novo lesions in native coronary arteries < 30 mm in length mm in diameter 50% - 99% stenosis 2. "Off-label" or beyond FDA-approved use Lesion subsets Multivessel disease Left main disease Bifurcation lesions Chronic total occlusions (CTO) In-stent restenosis (ISR) Small vessels (<2.5 mm in diameter) or large vessels (>3.75 mm in diameter) Long lesions requiring multiple or overlapping stents Saphenous vein grafts (SVG) Thrombus containing lesions (acute MI) High-risk patient subsets Diabetics Renal dysfunction DES-drug-eluting stent; FDA-Food and Drug Administration; MI -myocardial infarction. The TAXUS PES was developed almost simultaneously with the SES, gaining regulatory approval 12 months later. It was critically evaluated by a number of randomized trials most of which demonstrated a significantly lower rate of late loss, angiographic binary restenosis, and repeat revascularization with PES compared with BMS that is consistent across different patient groups including those with simple lesions, STEMI, lesions in the unprotected left main stem (UPLMS), and complex lesions 1. 2
3 VV Jain & S Yelwatkar It was natural that SES would have been compared to PES and so it was done by many randomized trials. With respect to clinical outcomes, a meta-analysis of 16 randomized trials of SES versus PES, which included 8,695 patients and, where possible, patient level data, reported significant reductions in TLR (hazard ratio [HR]: 0.74, 95% confidence interval [CI]: 0.63 to0.87, p <0.001) and ST (HR: 0.66, 95% CI: 0.46 to 0.94, p=0.02) with SES, whereas no significant differences in death (HR: 0.92, 95% CI: 0.74 to 1.13, p = 0.43), or MI (HR: 0.84, 95% CI: 0.69 to 1.03, p = 0.10) were noted at a median of 2-year follow-up 16. Second generation DES The initial coronary stents were composed of 316L stainless steel since this material is radioopaque and provides adequate radial strength to maintain arterial scaffolding with minimal acute recoil. An alternative to stainless steel is cobalt chromium (CoCr), which exhibits superior radial strength and improved radio-opacity, allowing for thinner stent struts that may reduce restenosis 17. Thinner struts can also lead to a reduction in device profile and, hence, an improvement in stent deliverability to the target lesion. The 2 second-generation DES that are currently approved by the U.S. FDA utilize CoCr, and elute "limus" drugs with the aid of more biocompatible polymers than are found on the first-generation DES. DES vs. BMS in today's real world Despite the benefits of DES, there is still a role for BMS in the management of patients with CAD. Though the recommendations promote DES more than BMS and as against the popular thinking, DES are far less used than BMS in the real world. Ultimately, the decision to implant a BMS is guided by both clinical and economic factors. We have already discussed the net clinical benefits of DES over BMS, and no discussion of stents can be completed without its economic implications. Some studies indicate that DES may be cost effective or even cost saving with specific patients, such as those who have lesions with a high risk for restenosis such as diabetic patients, long lesions, and lesions in vessels with small diameters. In the BASKET study 18, for example, DES was more effective and less expensive for vessels < 3.0 mm diameter. For vessels > 3.0 mm diameter, although the overall cost per qualityadjusted life-year gained was 39,641 ($59,392), subgroup analysis revealed that the cost per quality-adjusted life-year gained was 6,863 ($10,282) for off-label use, 3,471 ($5,200) for lesions > 24 mm in length, and 300 ($450) for patients > 65 years of age. Conversely, other studies report an incremental cost-effectiveness ratio of > 200,000 Canadian dollars per quality-adjusted life year-indicating DES is not cost effective. Nevertheless, a recent systematic review evaluated 19 different cost-effectiveness studies that mainly reported results at 1 year, and concluded that the cost effectiveness of DES was unfavorable compared with that of BMS. That was primarily because, although the use of DES was associated with a higher initial cost ( 700 [$1,060]), they did not increase life expectancy, produced only a small relative reduction in rates of repeat procedures, and led to only a short duration of improved quality of life 19. Future of coronary stenting Despite all the benefits of drug-eluting stents (DES), concerns have been raised over their long-term safety, with particular reference to 3
4 Coronary stents - past, present and future. stent thrombosis. In an effort to address these concerns, newer stents have been developed that include: DES with biodegradable polymers, DES that are polymer free, stents with novel coatings, and completely biodegradable stents. Many of these stents are currently undergoing pre-clinical and clinical trials; however, early results seem promising. Table 2 : Various new stents under development and trials Metallic DES with durable polymers. a. New polymer technology : Endeavor Resolute-zotarolimus-eluting stent (ZES) b. New antiproliferative agents: Elixir DESyne novolimus-eluting stent (NES). c. New metal stent platforms : platinum chromium Element stent platform. 2. DES with biodegradable polymers a. Sirolimus based- SUPRALIMUS stent i. EXCEL stent NEVO stent b. Biolimus A9 based i. BIOMATRIX stent i NOBORI stent XTENT custom NX stent c. Myolimus eluting stent d. Paclitaxel eluting stent i. INFINNIUM stent i JACTAX stent SYNERGY stent 3. Non-polymeric DES a. YUKON DES b. BioFreedom c. VESTAsyn Sirolimus eluting stent d. Amazonia Pax 4. Stents with novel coatings a. Catania Stent b. Titan-2 stent c. Genous Bioengineered R stent 5. Biodegradable stents a. PLLA stent- IGAKI TAMAI stent b. Abott vascular bio-reabsobable vascular scaffold(bvs) 6. Self expanding stents 7. Drug eluting ballons Conclusions : Coronary stents are an important component of percutaneous coronary revascularization. Many limitations of BMS were overcome with DES. It comes with a higher cost and is only associated with late stent thrombosis. DES has expanded the horizon of PCI which is being offered to patients with complex CAD and diabetes. There is a lot more novel DES in the developmental phases which look promising. References : 1. Garg S, Serruys PW. Coronary stents: current status. Am Coll Cardiol 2010; 56(10 Suppl): S Arjomand H, Turi ZG et al. Percutaneous coronary intervention: historical perspectives, current status, and future directions. Am Heart J 2003; 146(5): Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301: Serruys PW, Kutryk MJB, Ong ATL. Coronaryartery stents. N Engl J Med 2006; 354: Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intra-vascular stents to prevent 4
5 VV Jain & S Yelwatkar occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987; 316: Roubin GS, Cannon AD, Agrawal SK, et al. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation 1992; 85: Serruys PW, de Jaegere P, Kiemeneij F, et al., for the Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: Fischman DL, Leon MB, Baim DS, et al., for the Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331: Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334: Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995; 91: Jeremias A, Kirtane A. Balancing efficacy and safety of drug-eluting stents in patients undergoing percutaneous coronary intervention. Ann Intern Med 2008; 148: Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and threedimensional intravascular ultrasound study. Circulation 2001; 103: Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: Instructions for Use: CYPHER Sirolimuseluting Coronary Stent on RAPTOR Overthe-Wire Delivery System and CYPHER Sirolimus-eluting Coronary Stent RAPTORRAIL Rapid Exchange Delivery System. Available at: p020026c.pdf. 15. Directions for Use: TAXUS EXPRESS2 Paclitaxel-Eluting Coronary Stent System. Available at: Schomig A, Dibra A, Windecker S, et al. A metaanalysis of 16 randomized trials of sirolimuseluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: Kereiakes DJ, Cox DA, Hermiller JB, et al. Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol 2003; 92: Pfisterer M, Brunner-La Rocca HP, Rickenbacher P, et al. Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. Eur Heart J 2009; 30: Neyt M, Van Brabandt H, Devriese S, De Laet C. Cost-effectiveness analyses of drug eluting stents versus bare metal stents: a systematic review of the literature. Health Policy 2009; 91: Garg S, Serruys PW. Coronary stents: looking forward. J Am Coll Cardiol. 2010; 56(10 Suppl): S
Advances in Stent Technology
Nurse/Technologist Symposium Advances in Stent Technology Antonietta Tolentino, CCRN, MSN, ANP-C Adult Nurse Practitioner, Cardiac Catheterization Laboratory The Zena and Michael A. Weiner Cardiovascular
More informationMEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE
DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE Effective Date: October 1, 2015 Review Dates: 10/11, 10/12, 10/13, 8/14, 8/15 Date Of Origin: October 12, 2011 Status: Current Summary of Changes Clarifications:
More informationDuration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
More informationClinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up
Hellenic J Cardiol 45: 379-383, 2004 Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up PETROS S. DARDAS, DIMITRIS
More informationEuropean Heart Journal (1999) 20, 1014 1019 Article No. euhj.1998.1395, available online at http://www.idealibrary.com on
European Heart Journal (1999) 20, 1014 1019 Article No. euhj.1998.1395, available online at http://www.idealibrary.com on Working Group Report Indications for intracoronary stent placement: the European
More informationThe Bioresorbable Vascular Stent Dr Albert Ko
The Bioresorbable Vascular Stent Dr Albert Ko Dr Albert Ko MB BS, FRACP, FCSANZ Interventional/General Cardiologist Ascot Cardiology Symposium 2013 Treatment Goals for Coronary Artery Disease Relieve of
More informationLEADERS: 5-Year Follow-up
LEADERS: -Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable Polymer : Final Report of the LEADERS
More informationDrug-Eluting Coronary Stents. Paul Montero PGY-II University of Colorado Health Sciences Center Surgical Grand Rounds Resident Debate
Drug-Eluting Coronary Stents Paul Montero PGY-II University of Colorado Health Sciences Center Surgical Grand Rounds Resident Debate Outline Coronary Artery Disease Evolution of Percutaneous Coronary Intervention
More informationStatus of Drug-Eluting Coronary Stents
Status of Drug-Eluting Coronary Stents EVOLUTION OF PERCUTANEOUS CORONARY INTERVENTIONAL TECHNOLOGIES The introduction of percutaneous transluminal coronary angioplasty (PTCA) in the late1970s provided
More informationIntracoronary Stenting and. Robert A. Byrne, Julinda Mehilli, Salvatore Cassese, Franz-Josef Neumann, Susanne Pinieck, Tomohisa Tada,
Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis in Limus- Eluting Stents Intracoronary Stenting
More informationDrug-Eluting Balloons. Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam
Drug-Eluting Balloons Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam Potential conflicts of interest Speaker s name: Klaus Bonaventura
More informationCoronary-Artery Stents
review article Drug Therapy Coronary-Artery Stents Patrick W. Serruys, M.D., Ph.D., Michael J.B. Kutryk, M.D., Ph.D., and Andrew T.L. Ong, M.B., B.S. T he use of percutaneously introduced prosthetic devices
More informationThe Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program
The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program Jean Fajadet, MD, FESC Clinique Pasteur - Toulouse - France Disclosure statement Nothing to disclose Dedicated Delivery
More informationPreoperative Cardiac Stents Perioperative Management. Mark A. Taylor, MD Department of Anesthesia
Preoperative Cardiac Stents Perioperative Management Mark A. Taylor, MD Department of Anesthesia Revasc prior to NCS If it offered long term benefit-- --made sense to do it 1-22 vessel CAD by angiogram,
More informationAntonio Colombo MD on behalf of the SECURITY Investigators
Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy - The SECURITY Randomized Clinical Trial Antonio Colombo MD on behalf of the SECURITY
More informationORIGINAL ARTICLES: Morphology and Location of Restenosis Following Bare Metal Coronary Stenting
Page 1 / 7 ORIGINAL ARTICLES: Morphology and Location of Restenosis Following Bare Metal Coronary Stenting - Marc J. Schweiger, MD, Ehsan Ansari, MD, Gregory R. Giugliano, MD, *James Mathew, MD, Ashequl
More informationCilostazol versus Clopidogrel after Coronary Stenting
Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background
More informationPOST STENTING DUAL ANTIPLATELET THERAPY DURATION J BAUCUM MD FACC CAROLINA CARDIOLOGY GHS
POST STENTING DUAL ANTIPLATELET THERAPY DURATION J BAUCUM MD FACC CAROLINA CARDIOLOGY GHS Post Stenting Dual Antiplatelet Therapy When can I stop it? Intracoronary stenting is a frequent intervention for
More informationGUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA - A GUIDE FOR MANUFACTURERS AND NOTIFIED BODIES -
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Cosmetics and Medical Devices MEDDEV 2.7.1 Appendix 1 December 2008 GUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA
More informationPRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf
More informationPresenter: Marco Valgimigli, MD PhD, FESC Erasmus MC, Thoraxcenter Rotterdam The Netherlands
Comparing zotarolimus-eluting and bare-metal stent efficacy in selected high bleeding risk patients treated with a short dual antiplatelet therapy duration. A pre-specified analysis from the The Zotarolimuseluting
More informationControversies in the use & implementation of drug-eluting stent technology
Review Article Indian J Med Res 136, December 2012, pp 926-941 Controversies in the use & implementation of drug-eluting stent technology Brandon K. Itagaki * & Somjot S. Brar *,** * Regional Cardiac Cath
More informationDual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute
Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical
More informationRepeat Coronary Revascularization Procedures after Successful Bare-Metal or Drug-Eluting Stent Implantation
Original Contribution Repeat Coronary Revascularization Procedures after Successful Bare-Metal or Drug-Eluting Stent Implantation Cynthia A. Yock, MS, J. Michael Isbill, MS, Spencer B. King III, MD, Mark
More informationAntiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty
Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor
More informationANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head
ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION
More informationA Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III
A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III Gilles Montalescot, MD, PhD Pitié-Salpêtrière Hospital, Paris, France
More informationPooled RESOLUTE Clinical Program
The Relationship Between Short and Long-term Antiplatelet Therapy Use and Stent Thrombosis Following Percutaneous Coronary Intervention With the Resolute Zotarolimus-eluting Stent Pooled RESOLUTE Clinical
More informationCopenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark
Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-elevation myocardial infarction 3 year follow-up of the randomised trial Peter Clemmensen, Henning Kelbæk,
More informationIncidence of stent thrombosis and adverse cardiac events 5 years after sirolimus stent implantation in clinical practice
Interventional Cardiology Incidence of stent thrombosis and adverse cardiac events 5 years after sirolimus stent implantation in clinical practice Jean-Jacques Goy, MD, a Philip Urban, MD, b Urs Kaufmann,
More informationOstial LAD: Single stent approach is the best. Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI
Ostial LAD: Single stent approach is the best Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI Chair, Interventional Cardiology Sanatorio San Lucas Instituto Alexander Fleming Buenos
More informationPayment policies are potentially a strong driver of diffusion of
Medical Devices Diffusion Of New Technology And Payment Policies: Coronary Stents The implementation of a higher payment rate for stenting did not drive the acceleration of the technology s diffusion,
More informationUniversity of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial
Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park MD PhD Seung-Jung Park, MD, PhD, University of Ulsan
More informationRounds CARDIOLOGYTM. Percutaneous coronary intervention in the management of coronary artery disease. www.cardiologyrounds.ca.
Now Now available available on on the the Internet Internet www.cardiologyrounds.ca A U G U S T / S E P T E M B E R 2 0 0 1 volume VI, issue 7 CARDIOLOGYTM Rounds AS PRESENTED IN THE ROUNDS OF THE DIVISION
More informationCoronary Stents. Artery Disease Review of Firs00t 1. Coronary Stents in the Management of
Coronary Stents in the Management of Coronary Stents Artery Disease Review of Firs00t 1 S C Ng, FSCAP', Chen Sawatt, SRN, L K Foo, SRN, 0 Hitam, ASMLT, P G Khor, ASMLT, Y K Lee, ASMLT, *Ccmsuli:ant Interventional
More informationSAMPLE. Asia-Pacific Interventional Cardiology Procedures Outlook to 2020. Reference Code: GDMECR0061PDB. Publication Date: May 2014
Asia-Pacific Interventional Cardiology Procedures Outlook to 2020 Reference Code: GDMECR0061PDB Publication Date: May 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2
More informationThe infamous coronary stent saga
The infamous coronary stent saga Bernhard Meier Cardiology, Cardiovascular Department, Bern University Hospital, Bern, Switzerland Summary Against all odds, as a foreign body in a coronary artery was considered
More informationReview of Intracoronary Radiation for In-Stent Restenosis
Review of Intracoronary Radiation for In-Stent Restenosis Robert Lew, MBBS, FRACP, Andrew Ajani, MD, Ron Waksman, MD, FACC Vascular Brachytherapy using beta and gamma radiation is the standard care for
More informationCardiovascular disease has become a dominant cause of
Abstract Immediate and Six-month Clinical Outcome of Percutaneous Coronary Intervention in a Tertiary Hospital in the Sultanate of Oman Panduranga Prashanth, Mohamed Mukhaini, Abdulla A. Riyami, Kadhim
More informationClinical Programs. Medtronic Coronary Stent Systems. driver BMS
Clinical Programs Medtronic Coronary Stent Systems Endeavor DES driver BMS July 2010 Contents Overview of Clinical Programs... 2 Drug-Eluting Stents ENDEAVOR I*... 4 ENDEAVOR II*... 6 ENDEAVOR II Continued
More informationTherapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
More informationUnderstanding Coronary Artery Disease, Cardiac Catheterization, and Treatment Options. A Guide for Patients
Understanding Coronary Artery Disease, Cardiac Catheterization, and Treatment Options A Guide for Patients Coronary Artery Disease If you or a member of your family has been diagnosed with coronary artery
More informationDo método diagnóstico ao terapêutico: a História da Hemodinâmica e da Cardiologia Intervencionista, em 15 minutos. Eulógio E Martinez
Do método diagnóstico ao terapêutico: a História da Hemodinâmica e da Cardiologia Intervencionista, em 15 minutos Eulógio E Martinez IVUS vs luminologia Positivo Negativo estenose TCE oclusão CD sístole
More informationEditorial. Adult Cardiology - Meta-analysis
Editorial Adult Cardiology - Meta-analysis Simple Versus Complex Bifurcation Stenting Strategies A Meta Analysis of Randomized Controlled Trials in the Drug Eluting Stent Era Ana Beatriz R. Medrano, MD
More information2015 European Coronary Stent New Product Innovation Award
2015 European Coronary Stent New Product Innovation Award 2015 Contents Background and Company Performance... 3 Industry Challenges... 3 New Product Attributes and Customer Impact... 3 Conclusion... 4
More informationCoronary Artery Bypass Graft Surgery vs Percutaneous Interventions in Coronary Revascularization A Systematic Review
Clinical Review & Education Review Coronary Artery Bypass Graft Surgery vs ercutaneous Interventions in Coronary Revascularization A Systematic Review Saswata Deb, MD; Harindra C. Wijeysundera, MD; Dennis
More informationIncidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice
Journal of the American College of Cardiology Vol. 52, No. 14, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.07.006
More informationCORONARY ARTERY BYPASS GRAFTS, STENTS, AND EXTRACORONARY CARDIAC DZ. Charles White MD
CORONARY ARTERY BYPASS GRAFTS, STENTS, AND EXTRACORONARY CARDIAC DZ Charles White MD Director of Thoracic Imaging Department of Radiology University of Maryland CORONARY ARTERY BYPASS GRAFTS First performed
More informationCORONARY STENTS: CLINICAL EXPERIENCE AND COST -EFFECTIVENESS
Canadian Coordinating Office for Health Technology Assessment CORONARY STENTS: CLINICAL EXPERIENCE AND COST -EFFECTIVENESS CCOHTA Report 1997: 1E Additional copies of Coronary Stents: Clinical Experience
More informationImpact of Drug-Eluting Stents Among Insulin-Treated Diabetic Patients
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 2, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2008.02.005 Impact of
More informationHigh incidence of thrombus formation at 18 months after paclitaxel-eluting stent implantation: Angioscopic comparison with sirolimus-eluting stent
High incidence of thrombus formation at 18 months after paclitaxel-eluting stent implantation: Angioscopic comparison with sirolimus-eluting stent Masahiko Hara, MD, Masami Nishino, MD, Masayuki Taniike,
More informationWill Stents of New Technology Replace Coronary Artery Bypass Surgery?
HOSPITAL CHRONICLES 2006, SUPPLEMENT: 123 127 CARDIOLOGY UPDATE 2006 Will Stents of New Technology Replace Coronary Artery Bypass Surgery? Manolis Vavuranakis, MD A B S T R A C T Hippokration University
More informationDrug-Eluding Stents as an Alternative to Traditional Stenting in the Treatment of Coronary Artery Disease
TITLE: Drug-Eluding Stents as an Alternative to Traditional Stenting in the Treatment of Coronary Artery Disease AUTHOR: Mitchell D. Feldman, MD, M.Phil. Professor of Medicine Division of General Internal
More informationOptimal Duration of Dual Antiplatelet Therapy
Optimal Duration of Dual Antiplatelet Therapy Luis A Guzman, MD, FACC, FSCAI Associate Professor of Medicine Director, Cardiac and Vascular Cath Lab University of Florida College of Medicine - Jacksonville
More informationExperience of Direct Coronary Stenting at National Institute of Cardiovascular Diseases
Experience of Direct Coronary Stenting at National Institute of Cardiovascular Diseases T. Masood,T. Sagheer,D. Jan,N. Qamar,A.M.A. Faruqui ( National Institute of Cardiovascular Diseases (NICVD), Karachi.
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationPerspectives on the Selection and Duration of Dual Antiplatelet Therapy
Perspectives on the Selection and Duration of Dual Antiplatelet Therapy Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University
More informationMajestic Trial 12 Month Results
Majestic Trial 12 Month Results S.Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA ACADEMIC HOSPITALS Flensburg of Kiel University Ev.-Luth. Diakonissenanstalt zu Flensburg Knuthstraße 1, 24939 FLENSBURG Dept.
More informationOrsiro Hybrid Drug Eluting Stent Industry's first hybrid DES
Vascular Intervention Drug Eluting Stents Orsiro Orsiro Hybrid Drug Eluting Stent Industry's first hybrid DES Orsiro An ideal combination of passive and active components The Orsiro Hybrid Drug Eluting
More informationRotational Atherectomy for the Treatment of In-Stent Restenosis
Home SVCC Area: English - Español - Português Rotational Atherectomy for the Treatment of In-Stent Restenosis Steven L. Goldberg, MD Cardiac Catheterization Laboratory, University of Washington Medical
More informationέΰζβν αππ έκυ,νσϊίία κν1γν πλδζέκυνβί1γ π ηία δεόμνκαλ δκζόΰκμ, θν δ υγυθ άμνγνκαλ /εάμ ΚζδθδεάμΝ υλωεζδθδεάμν
ΝΠθ ζζάθδκνσθϋ λδκν έΰκ μνεδν ιωθκ κεκη δεάμνι λδεάμ έΰζβν έκ,νσϊίί κν1γν λδζέκνβί1γ Α Α φ ; έζ δκμννένσθόμ ηί δεόμνκλ δκζόΰκμ, θν δ γθ άμνγνκλ /εάμ ΚζδθδεάμΝ λωεζδθδεάμν ένivus Scientific Director, Mediolanum
More informationESC PCI Guidelines: / Sigmund Silber et al. 1
For the first time! ESC PCI Guidelines: / Sigmund Silber et al. 1 in 2002: 649.332 in 2002: 541.964 ESC PCI Guidelines: Introduction and Definitions / Sigmund Silber et al. 2 ESC PCI Guidelines: Introduction
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
European Medicines Agency London, 22 March 2007 Doc. Ref. EMEA/CHMP/EWP/110540/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE DEVELOPMENT OF MEDICINAL SUBSTANCES CONTAINED
More informationMy patient has a coronary stent : concerns for the anaesthetist
My patient has a coronary stent : concerns for the anaesthetist Lines D, Chris Hani Baragwanath Academic Hospital Correspondence to: Des Lines, e-mail: lines@pixie.co.za Peer reviewed Medpharm ;55(3)(Suppl
More informationThe Pantera Lux Paclitaxel DEB Device Description and Clinical Studies. Christoph Hehrlein, University Clinic Freiburg i.br.
The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies Christoph Hehrlein, University Clinic Freiburg i.br. Germany Disclosure Statement of Financial Interest Within the past 12 months,
More informationDual Antiplatelet Therapy Beyond One Year in Patients Receiving Coronary Stents for Treatment of Acute Coronary Syndromes
Dual Antiplatelet Therapy Beyond One Year in Patients Receiving Coronary Stents for Treatment of Acute Coronary Syndromes Robert W. Yeh, Dean J. Kereiakes, P. Gabriel Steg, Stephan Windecker, Michael J.
More informationCalifornia Health and Safety Code, Section 1256.01
California Health and Safety Code, Section 1256.01 1256.01. (a) The Elective Percutaneous Coronary Intervention (PCI) Pilot Program is hereby established in the department. The purpose of the pilot program
More informationGuidance on the use of coronary artery stents
NHS National Institute for Clinical Excellence Guidance on the use of coronary artery stents Technology Appraisal 71 October 2003 Technology Appraisal Guidance 71 Guidance on the use of coronary artery
More informationTAXUS Express 2. Paclitaxel-Eluting Coronary Stent System. Patient Information Guide
TAXUS Express 2 Paclitaxel-Eluting Coronary Stent System Patient Information Guide 1 Table of Contents Coronary Artery Disease...2 Who Is at Risk?...3 Diagnosis of Coronary Artery Disease...3 Treatment
More informationIs There A LIfe for DES after discontinuation of Clopidogrel
Chicago 2014 Is There A LIfe for DES after discontinuation of Clopidogrel Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin:
More informationEarly healing after treatment of coronary lesions by everolimus, or biolimus eluting bioresorbable polymer stents
Early healing after treatment of coronary lesions by everolimus, or biolimus eluting bioresorbable polymer stents One-month results of the study Ida Riise Balleby 1, Trine Krejberg Ørhøj 1, Christian Juhl
More informationCoronary Stents. What is a Coronary Artery stent?
What is a Coronary Artery stent? Coronary Stents A coronary stent is stainless tube with slots. It is mounted on a balloon catheter in a "crimped" or collapsed state. When the balloon of is inflated, the
More informationYukon Choice DES + Translumina - The polymer-free DES solution. www.translumina.de. Coronary Stent System for Drug Application
Coronary Stent System for Drug Application Yukon Choice DES + new catheter polymer-free DES Translumina - The polymer-free DES solution www.translumina.de A First Class Stent The YUKON Choice DES+ is the
More informationJUL 2 2008. Ms. Kendra Basler Regulatory Affairs Associate Abbott Vascular Cardiac Therapies 3200 Lakeside Drive Santa Clara, CA 95054-2807
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service JUL 2 2008 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Ms. Kendra Basler Regulatory Affairs Associate Abbott Vascular
More informationEuropean Cardiology. Volume 6 Issue 4 Extract. Svelte Acrobat Stent-On- A-Wire Coronary Stent System. J Ribamar Costa Jr and Alexandre Abizaid
European Cardiology Volume 6 Issue 4 Extract Svelte Acrobat Stent-On- A-Wire Coronary Stent System J Ribamar Costa Jr and Alexandre Abizaid Instituto Dante Pazzanese de Cardiologia, São Paulo www.touchcardiology.com
More informationAngioplasty and Stent Education Guide
Angioplasty and Stent Education Guide Table of Contents Treating coronary artery disease...2 What is coronary artery disease...3 Coronary artery disease treatment options...4 What are coronary artery
More informationValidation of a Risk Score for Target Vessel Revascularization after Coronary Stent Implantation
Original Contribution Validation of a Risk Score for Target Vessel Revascularization after Coronary Stent Implantation a Alexandre S. Quadros, MD, PhD, b Fabiane Diemer, RN, b Dulce Welter, RN, Thais Modkowski,
More informationDrug-eluting stents versus bare metal stents for angina or acute coronary syndromes (Review)
Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes (Review) Greenhalgh J, Hockenhull J, Rao N, Dundar Y, Dickson RC, Bagust A This is a reprint of a Cochrane review, prepared
More informationNOVOSTE BETA-CATH SYSTEM
HOSPITAL INPATIENT AND OUTPATIENT BILLING GUIDE FOR THE NOVOSTE BETA-CATH SYSTEM INTRAVASCULAR BRACHYTHERAPY DEVICE This guide is intended solely for use as a tool to help hospital billing staff resolve
More informationDUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania
DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen
More informationObjectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
More informationReview Article A review on percutaneous coronary intervention vs. coronary artery bypass graft surgery.
Kathmandu University Medical Journal (2003) Vol. 1, No. 4, Issue 4, 284-287 Review Article A review on percutaneous coronary intervention vs. coronary artery bypass graft surgery. Karki DB 1 Neopane A
More informationCARDIAC RISKS OF NON CARDIAC SURGERY
CARDIAC RISKS OF NON CARDIAC SURGERY N E W S T U D I E S & N E W G U I D E L I N E S W. B. C A L H O U N, M D, F A C C 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management
More informationCost-efficacy in interventional cardiology: results from the EPISTENT study
4 Cost-efficacy in interventional cardiology: results from the EPISTENT study Zwart-van Rijkom JEF (1,2), Van Hout BA (3) (1) Institute for Medical Technology Assessment, Erasmus University Rotterdam,
More informationWOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast
WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION Van Crisco, MD, FACC, FSCAI First Coast Conflicts of Interest I have been a paid consultant and speaker for AstraZeneca, makers of
More informationTECHNOLOGICAL INNOVATION FOR CORONARY STENTS Francesco Migliavacca
LABORATORY OF BIOLOGICAL STRUCTURE MECHANICS www.labsmech.polimi.it TECHNOLOGICAL INNOVATION FOR CORONARY STENTS Francesco Migliavacca Erice, 1 maggio 2015 International School of Cardiac Surgery Introduction
More informationShould EDTA Chelation Therapy be Used Instead of Long-term Clopidogrel plus Aspirin to Treat Patients at Risk from Drug-Eluting Stents?
Should EDTA Chelation Therapy be Used Instead of Long-term Clopidogrel plus Aspirin to Treat Patients at Risk from Drug-Eluting Stents? L. Terry Chappell, MD Abstract The recently discovered increased
More informationClinical Results of Unprotected Left Main Coronary Stenting
Original Articles IMAJ VOL 11 MARCH 2009 Clinical Results of Unprotected Left Main Coronary Stenting Itsik Ben-Dor MD, Hana Vaknin-Assa MD, Eli Lev MD, David Brosh MD, Shmuel Fuchs MD, Abid Assali MD and
More informationSteven J. Yakubov, MD FACC For the CoreValve US Clinical Investigators
Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From the CoreValve US Pivotal Trial Steven J. Yakubov,
More informationSeQuent Please balloon catheter for in-stent coronary restenosis. NICE medical technology guidance 1. Issue date: December 2010
Issue date: December 2010 SeQuent Please balloon catheter for in-stent coronary restenosis NICE medical technology guidance 1 1 NICE medical technology guidance 1 NICE medical technology guidance 1 SeQuent
More informationAn Economic Analysis of Drug Eluting Coronary Stents
An Economic Analysis of Drug Eluting Coronary Stents A Québec Perspective AGENCE D ÉVALUATION DES TECHNOLOGIES ET DES MODES D INTERVENTION EN SANTÉ 41 An Economic Analysis of Drug Eluting Coronary Stents
More informationPolymer-Based, Paclitaxel-Eluting TAXUS Liberté Stent in De Novo Lesions: The Pivotal TAXUS ATLAS Trial
Polymer-Based, Paclitaxel-Eluting Stent in De Novo Lesions: The Pivotal TAXUS ATLAS Trial Mark A. Turco, John A. Ormiston, Jeffrey J. Popma, Lazar Mandinov, Charles D. O'Shaughnessy, Tift Mann, Thomas
More informationAntiaggreganti. STEMI : cosa c è di nuovo? Heartline 2015. Genova 13 14 Novembre 2015
Heartline 2015 Genova 13 14 Novembre 2015 STEMI : cosa c è di nuovo? Antiaggreganti Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia STEMI : cosa c è di nuovo?
More informationSCORM. For more patient education, please visit www.cypherusa.com
Attach Label Understanding Coronary Artery Disease, Cardiac Catheterization, and Treatment Options Stent Implant Card CYPHER Sirolimus-eluting Coronary Stent SCORM P.O. Box 025700 Miami, FL 33102-5700,
More informationCoronary Bifurcation Treatment: Update from the European Bifurcation Club. Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy)
Coronary Bifurcation Treatment: Update from the European Bifurcation Club Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy) Disclosure Statement of Financial Interest Within the past 12 months, I
More informationA Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs
A Patient s Guide to Primary and Secondary Prevention of PATIENT EDUCATION GUIDE What Is Cardiovascular Disease? Cardiovascular disease (CVD) is a broad term that covers any disease of the heart and circulatory
More informationOPTIMIZE: A Prospective, Randomized Trial of 3 Months Versus 12 Months of Dual Antiplatelet Therapy with the Endeavor Zotarolimus-Eluting Stent
Main Arena III - Plenary Sessions XVI Late Breaking Clinical Trials III - Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of 3 Months Versus 12 Months of Dual Antiplatelet Therapy
More informationFundación Favaloro. Fundación Favaloro
Superficial Femoral Artery: Which h Factors Influence Patency? Oscar A. Mendiz.MD.FACC.FSCAI Chairman hi of Interventional Cardiology dil March 2010 Name: Oscar A. Mendiz Disclosure I have the following
More informationIs Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient?
Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient? --- NIRS-IVUS TVC Imaging Adds Additional Information for the Heart Team Dr. Luis Tami Memorial Regional Hospital
More informationINTRODUCTION. Key Words:
Case Report Acta Cardiol Sin 2014;30:485 489 Successful Revascularization of Chronic Total Occlusion in Native Coronary Arteries through an Occluded Saphenous Bypass Vein Graft: A Retrograde Alternative
More information